Drs Samuel Klempner and Yelena Janjigian provide clinical pearls for understanding, detecting, and treating GEJ adenocarcinoma.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999882. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

The Role of Staging Laparoscopy for Gastric Cancer Patients: Current Evidence and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/37444535/

MATTERHORN: Phase III Study of Durvalumab Plus FLOT Chemotherapy in Resectable Gastric/Gastroesophageal Junction Cancer https://pubmed.ncbi.nlm.nih.gov/35535555/

Neoadjuvant and Adjuvant Pembrolizumab Plus Chemotherapy in Locally Advanced Gastric or Gastro-oesophageal Cancer (KEYNOTE-585): An Interim Analysis of the Multicentre, Double-Blind, Randomised Phase 3 Study https://pubmed.ncbi.nlm.nih.gov/38134948/

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer https://pubmed.ncbi.nlm.nih.gov/33789008/

Pathological Regression of Primary Tumour and Metastatic Lymph Nodes Following Chemotherapy in Resectable OG Cancer: Pooled Analysis of Two Trials https://pubmed.ncbi.nlm.nih.gov/36966233/

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction: The Randomized Phase 2 IKF-S628 Moonlight Trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4050

The KEYNOTE-811 Trial of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric Cancer https://pubmed.ncbi.nlm.nih.gov/34912120/

Relation Between Mismatch Repair Status, Chemoresponse, Survival and Anatomic Location in Gastroesophageal Adenocarcinoma https://pubmed.ncbi.nlm.nih.gov/36792128/

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Esophageal and Esophagogastric Junction Cancers https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial https://pubmed.ncbi.nlm.nih.gov/38382001/

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/33983395/

DPYD and UGT1A1 Pharmacogenetic Testing in Patients With Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation https://pubmed.ncbi.nlm.nih.gov/32985005/